12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Deals

miRagen, Santaris, Servier deal

Servier exercised its right to add a third target to a 2011 deal with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. Servier's target selection triggered the first undisclosed milestone payment to miRagen. The deal now includes the undisclosed new...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >